Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
GLP-1 therapies are expensive, and payers are understandably interested in outcomes data to support value based contracting arrangements
Denial rate for diabetes-indication GLP-1s is approximately 18% on first submission, usually due to incomplete documentation of prior medication trials
The UK's medicine watchdog, Nice, has recommended that patients receive at least a year of ongoing advice and tailored action plans after they've stopped treatment, helping them to make practical changes to their lives so they can keep the weight off and most importantly, stay healthy
doi: 10.3390/ijms19010110 77 KinuthiaUMWolfALangmannT
Retatrutide is a triple agonist nicknamed Triple G for the three G-protein coupled receptors it targets at once: GIP, GLP-1, and glucagon
Obesity A body mass index (BMI) of 30 or over means youre obese
US$ 24.28
US$ 21.97
US$ 22.21
US$ 22.53
US$ 20.96
US$ 28.43
US$ 28.82
US$ 25.69
